Clinical Trials
11 trialsNCT03761225 2023-09-29
Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
AB Science
Phase 3 Completed
NCT04333108 2023-05-06
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
AB Science
Phase 3 Unknown
NCT00812240 2023-02-01
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
AB Science
Phase 3 Terminated
NCT01694277 2020-12-08
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
AB Science
Phase 3 Completed
NCT03766295 2020-12-08
Masitinib Plus Gemcitabine in Pancreatic Cancer
AB Science
Phase 3 Completed
NCT01280565 2020-11-05
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
AB Science
Phase 3 Terminated
NCT00814073 2019-12-03
AB06006
AB Science
Phase 3 Completed
NCT02605044 2019-02-11
Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer
AB Science
Phase 3 Terminated
NCT01470131 2018-12-19
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
AB Science
Phase 3 Terminated
NCT00789633 2018-12-17
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
AB Science
Phase 3 Completed
NCT02009423 2018-12-14
Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
AB Science
Phase 3 Terminated